[144] UNITED THERAPEUTICS Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics (UTHR) Form 144 summary: This notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,891,277.50, listing an approximate sale date of 09/30/2025 on NASDAQ. The securities were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, totaling 294,000 shares acquired at that time. The filing also discloses prior sales by Martine Rothblatt in September 2025 totaling 64,000 shares sold across multiple dates, with daily gross proceeds shown per trade. Outstanding shares are listed as 45,230,000, providing context for the reported transactions.

Positive

• None.

Negative

• Insider sales activity: Martine Rothblatt sold 64,000 shares across September 2025 dates, which may be viewed as insider liquidity.
• Proposed immediate sale: The Form 144 notifies a planned sale of 4,000 shares valued at $1,891,277.50 to occur on 09/30/2025.

Insights

Securities Analyst

TL;DR: Insider sells were frequent in September 2025 but represent a small fraction of outstanding shares and appear orderly.

The filing shows a proposed 4,000-share sale valued at $1.89 million and discloses 64,000 shares sold by the same insider earlier in September 2025. Relative to the 45.23 million shares outstanding, these transactions are small in percentage terms (well under 1%), indicating limited direct dilution or market impact from these dispositions. The securities originated from an executive deferred compensation grant dated March 15, 2016, suggesting these are previously vested holdings rather than newly issued shares. For investors, the filing documents insider liquidity activity but does not itself indicate company operational changes.

Corporate Governance Expert

TL;DR: Documented insider sales follow Rule 144 procedures; disclosure aligns with regulatory requirements.

The notice provides required detail on the seller, acquisition origin, and broker arrangement, indicating compliance with Rule 144 disclosure norms. The seller represents no undisclosed material adverse information in the remarks section, and the trades were executed through a broker on Nasdaq. While concentrated insider selling can raise governance questions, the magnitude here is modest relative to total shares outstanding and the timing and structure (sales from deferred compensation vested in 2016) point to personal liquidity rather than corporate governance changes. No information in this filing indicates any governance action by the board or management changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20th Floor NEW YORK NY 10017	4000	1891277.50	45230000	09/30/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672512.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736408.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723659.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/26/2025	4000	1712811.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/29/2025	4000	1702446.76

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does United Therapeutics' (UTHR) Form 144 disclose?

The filing discloses a proposed sale of 4,000 common shares valued at $1,891,277.50, acquired on 03/15/2016 under executive deferred compensation.

Who is the seller named in the UTHR Form 144?

The filer and seller identified is Martine Rothblatt, with securities acquired via executive deferred compensation on 03/15/2016.

How many UTHR shares were sold by the insider during September 2025?

The filing lists sales totaling 64,000 shares across multiple dates in September 2025, with daily gross proceeds provided for each trade.

Through which broker will the proposed UTHR sale be executed?

The proposed sale lists TD Securities (USA) LLC as the broker, with an address at 125 Park Ave, 20th Floor, New York, NY 10017.

What portion of UTHR's outstanding shares does the proposed sale represent?

The filing shows 45,230,000 shares outstanding; the proposed 4,000-share sale is a very small fraction of total shares outstanding.